// App-Quantinova.ai

8504 : Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts).

Researchers

Presenter

  • Shirish M. Gadgeel

Principal Investigators

  • Jaclyn Ventimiglia

  • Gregory Peter Kalemkerian

  • Mary J. Fidler

  • Wei Chen

  • Ammar Sukari

  • Balazs Halmos

  • Julie Boerner

  • Antoinette J. Wozniak

  • Cathy Galasso

  • Nathan A. Pennell

Medical Centers

  • Karmanos Cancer Institute, Detroit, MI

  • University of Michigan, Ann Arbor, MI

  • Rush University Medical Center, Chicago, IL

  • Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detriot, MI

  • Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

  • Cleveland Clinic, Cleveland, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02359019

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved